Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Sanofi plans to spend $550 million on a vaccine-manufacturing facility in Neuville-sur-Saône, France, a 5-year project expected to create 200 full-time jobs. Sanofi will also invest $135 million in an R&D facility in Marcy-l’Étoile. Geared toward meeting production needs in any future pandemics, the plant will feature a central unit housing several modules that can make 3–4 vaccines simultaneously. Sanofi and GlaxoSmithKline announced in April that they are collaborating on the development of an adjuvanted COVID-19 vaccine, for which the French firm will contribute an antigen based on recombinant DNA technology.
This article has been sent to the following recipient: